Related Experiment Video
Updated: Jul 10, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
New molecular targets in malignant gliomas
John F de Groot1, Mark R Gilbert
1Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Purpose Of Review:
The purpose of this review is to provide an update on the identification of novel molecular targets in neurooncology and their translation into clinical practice.
Recent Findings:
Basic research is providing novel insights into the complex molecular pathways involved in the pathogenesis of malignant glioma transformation and progression. By unraveling the intricate signaling cascades responsible for sustained proliferation, angiogenesis, invasion and resistance to apoptosis in glioma, we are now confronted with an ever-expanding list of molecular targets. Clinical studies using single targeted therapies have been disappointing, therefore providing the impetus for novel combination drug trials. The potential for combination regimens brings the challenge of testing an exponentially growing number of treatments. Success will depend on an integration of novel treatment regimens and innovative trial designs combined with careful patient selection based on the results of molecular profiling of tumor tissue.
Summary:
Technologic advances in oncogenomics, proteomics and functional genomic screens (such as synthetic lethality) are providing mechanisms to rapidly identify the critical targets whose inactivation will lead to a substantive tumor growth arrest. Tumor tissue biomarkers that identify those tumors most likely to respond to a specific inhibitor are needed as a mechanism toward tailoring therapy to the individual patient with malignant glioma.
Insights
Identifying new molecular targets in neurooncology is crucial for treating malignant gliomas. Combination therapies and molecular profiling are key to advancing clinical practice for these brain tumors.
Area of Science:
- Neuro-oncology
- Molecular biology
- Cancer research
Background:
- Malignant gliomas involve complex molecular pathways driving tumor transformation and progression.
- Understanding signaling cascades is essential for targeting sustained proliferation, angiogenesis, invasion, and apoptosis resistance.
Purpose of the Study:
- To update on novel molecular targets in neuro-oncology.
- To discuss the translation of these targets into clinical practice.
Main Methods:
- Review of basic research on molecular pathways in glioma.
- Analysis of clinical studies on targeted therapies.
- Exploration of advances in oncogenomics, proteomics, and functional genomic screens.
Main Results:
- Basic research reveals numerous molecular targets for glioma.
- Single targeted therapies have shown disappointing results, necessitating combination trials.
- An increasing number of potential combination treatments require innovative trial designs and patient selection.
Conclusions:
- Technological advances facilitate rapid identification of critical targets for tumor growth arrest.
- Biomarkers are needed to tailor therapies for individual malignant glioma patients based on tumor molecular profiles.
